LNTH - Spark Newswire

3 minute read

Change Healthcare (CHNG) Q1 Earnings & Revenues Miss Estimates

August 5, 11:57 AM

Change Healthcare Inc. (NASDAQ: CHNG) reported first-quarter fiscal 2023 adjusted earnings per share (ETF:EPS) of 38 cents, which missed the Zacks Consensus Estimate of 39 cents by 2.6%. The bottom line declined 7.3% on a year-over-year basis.

ALKS

1 minute read

SVB Leerink Maintains Outperform on Lantheus Holdings, Raises Price Target to $110

By Benzinga Newsdesk

August 5, 9:48 AM

SVB Leerink analyst Roanna Ruiz maintains Lantheus Holdings (NASDAQ:LNTH) with a Outperform and raises the price target from $100 to $110.

LNTH

34 minute read

Earnings

Earnings Scheduled For August 4, 2022

By Benzinga Insights

August 4, 4:23 AM

Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.

AAOI

1 minute read

SVB Leerink Assumes Lantheus Holdings at Outperform, Announces Price Target of $100

By Benzinga Newsdesk

June 6, 4:40 AM

SVB Leerink analyst Roanna Ruiz assumes Lantheus Holdings (NASDAQ:LNTH) with a Outperform rating and announces Price Target of $100.

LNTH

3 minute read

The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio’s PRV; RMAT Designation For PolarityTE’s Product

By Vandana Singh

May 13, 10:38 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

BBIO

3 minute read

Lantheus Reports First Patient Dosed In Phase 2 Trial Of NM-01 To Monitor PD-L1 Expression In Non-Small Cell Lung Cancer Patients

By Benzinga Newsdesk

May 13, 8:09 AM

NM-01 is a novel technetium-99m SPECT imaging agent currently being developed for the assessment of PD-L1 expression in cancer cells NORTH BILLERICA, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc.

LNTH

2 minute read

Lantheus Highlights National Comprehensive Cancer Network, Society Of Nuclear Medicine, Molecular Imagine Have Updated Their Guidelines For Use Of Prostate Specific Membrane Antigen Imaging

By Benzinga Newsdesk

May 11, 8:22 AM

Lantheus Holdings, Inc. (“the Company”) (NASDAQ:LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence

LNTH

1 minute read

B. Riley Securities Initiates Coverage On Lantheus Holdings with Buy Rating, Announces Price Target of $91

By Benzinga Newsdesk

May 9, 6:14 AM

B. Riley Securities analyst Justin Walsh initiates coverage on Lantheus Holdings (NASDAQ:LNTH) with a Buy rating and announces Price Target of $91.

LNTH

3 minute read

Stocks That Hit 52-Week Highs On Monday

By Benzinga Insights

May 2, 11:39 AM

Monday's session saw 22 companies set new 52-week highs.

AMCI

1 minute read

Recap: Lantheus Holdings Q1 Earnings

By Benzinga Insights

April 29, 7:48 AM

Lantheus Holdings (NASDAQ:LNTH) reported its Q1 earnings results on Friday, April 29, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

LNTH

Feed Symbols: LNTH